Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of Angiotensin II Type 1 . Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organs In Vivo The metabolic pathway of Allisartan isoproxil is relatively simple, and Allisartan isoproxil is completely and directly converted to EXP-3174 by esterase during gastrointestinal absorption . Allisartan isoproxil\t(20, 80 and 320 mg/kg/day; po; for 26 weeks) decreases body weight at 80-320 mg/kg/day dose, in Sprague-Dawley rats . Allisartan isoproxil\t(30 mg/kg/day; po in diet; for 55 weeks) significantly decreases stroke-related death and prolongs lifespan in stroke-prone renovascular hypertensive rats (RHR-SP). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Femal and male Sprague-Dawley rats Dosage: 20, 80 and 320 mg/kg Administration: Result: Decreased body-weight gain at 320 mg/kg/day in both sexes as well as at the 80-mg/kg/day dose in females. Decreased erythrocyte parameters in males, and decreased heart weight and exacerbation of chronic progressive nephropathy (CPN) severity in males at 80 and 320 mg/kg/day. Form:Solid IC50& Target:Angiotensin II Type 1